Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Rasagiline

An irreversible monoamine oxidase B (MAO-B) inhibitor for Parkinson's disease, developed at the Technion in Haifa, Israel, by Moussa Youdim and John Finberg; approved in Europe in 2005 and in the United States in 2006. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It all began with selegiline, the molecule of Hungarian scientist Joseph Knoll: Youdim heard of it in 1972 and travelled to Budapest to obtain a sample.

RasagilineGo to the active ingredient →
RasagilineActive ingredientRasagilineCat. No. P-R017-001CAS 136236-51-6
1-IndanoneImpurity1-IndanoneCat. No. P-R017-013CAS 83-33-0
Indan-1-olImpurityIndan-1-olCat. No. P-R017-024CAS 6351-10-6

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.